Biosimilars & Value Biologics
Same biologic outcome. Smarter cost. The clinical outcomes your patients rely on — backed by verified quality, dual-source supply resilience, and 20–50% smarter cost options for hospitals, infusion units, and insured care programs across Africa.
Covering oncology, immunology, endocrinology, supportive and rare diseases.
Direct budget relief compared to originator reference biologics.
Stringent regulatory authority evaluated with verified PPB clearance.
Multiple verified manufacturing partners per molecule preventing stock-outs.
Value Biologics Across Every Major Clinical Class
Explore 39 verified biosimilars approved for therapeutic equivalence. Filter by clinical class to view originator mappings, indications, and institutional packs.
Adalimumab
Recombinant human IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-alpha) for severe inflammatory autoimmune conditions.
Request Molecule PackTrastuzumab
Targeted humanized monoclonal antibody designed to inhibit HER2 receptor proliferation in early and metastatic breast and gastric cancers.
Request Molecule PackBevacizumab
Angiogenesis inhibitor binding to VEGF-A, preventing tumor microvascular growth across colorectal, lung, renal, and glioblastoma regimens.
Request Molecule PackRituximab
Anti-CD20 chimeric antibody mediating B-cell lysis in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and severe rheumatoid arthritis.
Request Molecule PackPegfilgrastim & Filgrastim
Pegylated granulocyte colony-stimulating factor that stimulates bone marrow neutrophil production, reducing infection duration post-chemotherapy.
Request Molecule PackInfliximab
Chimeric monoclonal antibody neutralizing soluble and transmembrane TNF-alpha, establishing deep clinical mucosal healing in IBD and spondyloarthritis.
Request Molecule PackDenosumab
Human monoclonal antibody targeting RANK ligand to prevent osteoclast formation, protecting bone density and preventing skeletal-related events.
Request Molecule PackInsulin Glargine & Aspart
Interchangeable long-acting basal and rapid-acting mealtime insulin analogues engineered for glycemic stability and reduced nocturnal hypoglycemia.
Request Molecule PackEculizumab & Natalizumab
High-complexity biologic inhibitors targeting terminal complement protein C5 and alpha-4 integrins for paroxysmal hemoglobinuria and refractory MS.
Request Molecule PackWe Support the Whole Switch End to End
Moving from an originator to a verified biosimilar is both a clinical and an operational decision. Medserv and TheDOTMED support your pharmacy, clinical specialists, and formulary committees throughout the transition.
Identify the Switch
Reference biologic to verified biosimilar mapping, institutional utilization audits, and patient cohort eligibility reviews.
Assure Quality
FDA/EMA/WHO-PQ approved sourcing, PPB market registration audits, and batch Certificate of Analysis (COA) handshakes.
Support the Switch
Multidisciplinary substitution guidance, pharmacist interchangeability consensus packs, and clinician comparability sessions.
Sustain & Save
Multi-source supply resilience backed by 2–3 verified manufacturers per molecule and unbroken 2°C–8°C IoT telemetry logs.
Confidence in Every Consignment
Biologic therapy interruption is clinically unacceptable. Our dual-sourcing framework ensures uninterrupted care continuity.
2–3 Verified Sources
Dual-source agreements per molecule prevent vulnerability to single-plant shutdowns or export embargoes.
Validated 2°C–8°C
Continuous IoT climate data loggers inside qualified ISTA-7D passive shippers across all transit corridors.
Central GSDP Hub
Strategic buffer inventory held in our WHO-GSDP compliant Sunny Plaza warehouse in Nairobi.
24h Pharmacovigilance
Post-market surveillance, batch traceability, and direct adverse drug reaction (ADR) reporting triage.
Quality Governance & Verification
- Stringent Regulatory Approvals: Sourced exclusively from FDA, EMA, or WHO-Prequalified facilities.
- TraceLink Serialization: End-to-end 2D matrix barcode verification against counterfeit diversion.
- Batch-Level COA Release: Full analytical certificate handshakes provided with every hospital delivery.
- Digital Temperature Passports: Instant PDF sensor readout delivered to hospital pharmacy before sign-off.
- PPB Wholesale Authorization: Registered superintendent pharmacists supervising distribution corridors.
Clear Guidance on Biosimilar Equivalence & Sourcing
Have questions regarding comparability evidence, indication extrapolation, or substitution policies in African health systems? Find clinical answers below.
Biosimilars undergo rigorous "totality-of-the-evidence" comparability evaluations mandated by the WHO, FDA, and EMA. This involves comprehensive structural, physicochemical, non-clinical pharmacokinetic, and confirmatory clinical trials demonstrating zero clinically meaningful differences in efficacy, purity, safety, or immunogenicity.
When biosimilar comparability is demonstrated in one clinical indication, regulatory agencies permit extrapolation to other indications authorized for the reference product if the mechanism of action, receptor binding, and target pathology are identical.
Every consignment of biologics travels inside validated, phase-change passive thermal shippers with continuous digital IoT temperature loggers. Temperature compliance is validated against 2°C–8°C parameters and delivered directly as a digital PDF certificate upon receipt at hospital pharmacy doors.
Yes. Over 15 years of global real-world evidence involving hundreds of millions of patient days has demonstrated that switching from originator biologics to verified biosimilars produces identical clinical efficacy with no increased risk of immunogenicity or adverse reactions.
Medserv structures predictable, fixed-cost institutional agreements backed by multi-source manufacturer commitments, dedicated safety stock reserves, and custom health economics tracking for hospital pharmacy directors and insurer networks.
Switch with Confidence to Value Biologics
Talk to our clinical access specialists about a tailored biosimilars partnership that protects clinical quality, supply security, and your formulary budget.